13722
document
Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients : a short-term , prospective , randomized study . BACKGROUND Tubulointerstitial injury is a major feature of diabetic nephropathy and an important predictor of renal dysfunction . In 45 patients with type 2 diabetes mellitus ( DM ) , we prospectively analyzed urinary excretion of N-acetyl-beta-glucosaminidase ( NAG ) , a marker of tubular renal damage ; the potential relationship with urinary protein excretion ; and effects of pentoxifylline ( PTF ) administration . METHODS Forty-five patients with type 2 DM initially were compared with 15 healthy controls matched for age and sex . After randomization , PTF ( 1,200 mg/d ) was administered for 4 months to 30 patients and results were compared with data from a control group ( n = 15 ) . RESULTS Proteinuria and urinary NAG excretion were significantly greater in patients with DM with respect to healthy controls . Before PTF administration , baseline parameters were similar in both groups of patients with DM . At the end of the study , urinary protein excretion and NAG-creatinine ratios decreased in the active group from 920 +/- 522 mg/d and 14.3 +/- 16.9 U/g to 803 +/- 523 mg/d ( P < 0.001 ) and 10.5 +/- 9.3 U/g ( P < 0.05 ) , respectively . Conversely , proteinuria and urinary NAG excretion did not change in the control group . Regression analysis showed that urinary NAG excretion was significantly associated with duration of DM ( r = 0.61 ; P < 0.001 ) and proteinuria ( r = 0.51 ; P < 0.001 ) . CONCLUSION Urinary NAG excretion is elevated in patients with type 2 DM compared with healthy individuals and increases as nephropathy progresses . PTF administration is effective in reducing proteinuria and urinary NAG excretion in these patients . These findings suggest that PTF may have beneficial effects on tubulointerstitial damage in diabetic kidney disease .
13723
Intervention_Pharmacological
pentoxifylline
13724
Intervention_Pharmacological
pentoxifylline ( PTF )
13725
Intervention_Pharmacological
PTF
13726
Intervention_Control
control
13727
Intervention_Pharmacological
PTF
13728
Intervention_Pharmacological
PTF
13729
Outcome_Physical
Proteinuria and urinary NAG excretion
13730
Outcome_Physical
urinary protein excretion and NAG-creatinine ratios
13731
Outcome_Physical
proteinuria and urinary NAG excretion
13732
Outcome_Physical
urinary NAG excretion
13733
Outcome_Physical
proteinuria
13734
Outcome_Physical
Urinary NAG excretion
13735
Outcome_Physical
proteinuria and urinary NAG excretion
13736
Participant_Condition
type 2 diabetic patients :
13737
Participant_Condition
45 patients with type 2 diabetes mellitus ( DM )